Objective: To compare third-trimester size trajectory prediction errors (average transformed percent deviations) for three individualized fetal growth assessment methods.
Methods: This study utilized longitudinal measurements of nine directly measured size parameters in 118 fetuses with normal neonatal growth outcomes. Expected value (EV) function coefficients and variance components were obtained using two-level random coefficient modeling. Growth models (IGA) or EV coefficients and variance components (PLM and CPM) were used to calculate predicted values at ∼400 third-trimester time points. Percent deviations (%Dev) calculated at these time points using all three methods were expressed as percentages of IGA MA-specific reference ranges [transformed percent deviations (T%Dev)]. Third-trimester T%Dev values were averaged (aT%Dev) for each parameter. Mean ± standard deviation's for sets of aT%Dev values derived from each method (IGA, PLM and CPM) were calculated and compared.
Results: Mean aT%Dev values for nine parameters were: (i) IGA: -4.3 to 5.2% (9/9 not different from zero); (ii) PLM: -32.7 to 25.6% (4/9 not different from zero) and (iii) CPM: -20.4 to 17.4% (5/9 not different from zero). Seven of nine systematic deviations from zero were statistically significant when IGA values were compared to either PLM or CPM values. Variabilities were smaller for IGA when compared to those for PLM or CPM, with (i) 5/9 being statistically significant (IGA versus PLM), (ii) 2/9 being statistically significant (IGA versus CPM) and (iii) 5/9 being statistically significant (PLM versus CPM).
Conclusions: Significant differences in the agreement between predicted third-trimester size parameters and their measured values were found for the three methods tested. With most parameters, IGA gave smaller mean aT%Dev values and smaller variabilities. The CPM method was better than the PLM approach for most but not all parameters. These results suggest that third-trimester size trajectories are best characterized by IGA in fetuses with normal growth outcomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6091864 | PMC |
| http://dx.doi.org/10.3109/14767058.2014.995083 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Catalytic peptide-based coacervates for enhanced function through structural organization and substrate specificity.
Nat Commun
October 2024
Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Av. da República, 2780-157, Oeiras, Portugal.
Liquid-liquid phase separation (LLPS) in living cells provides innovative pathways for synthetic compartmentalized catalytic systems. While LLPS has been explored for enhancing enzyme catalysis, its potential application to catalytic peptides remains unexplored. Here, we demonstrate the use of coacervation, a key LLPS feature, to constrain the conformational flexibility of catalytic peptides, resulting in structured domains that enhance peptide catalysis.
View Article and Find Full Text PDFTriplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
N Engl J Med
July 2022
From the Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center (P.G.R., M.F., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), the Department of Data Science, Dana-Farber Cancer Institute (S.J.J., K.H.), the Division of Hematology and Oncology, Boston Children's Hospital (E.A.W.), the Center for Multiple Myeloma, Massachusetts General Hospital (N.S.R., A.J.Y.), Harvard Medical School (P.G.R., S.J.J., E.A.W., N.S.R., A.J.Y.. M.F., K.H., M.K.S., K.M., M.E.M., A.A.Z., O.N., R.L.S., J.P.L., C.P.-P., I.M.G., K.C.A., N.C.M.), and the Veterans Affairs Boston Healthcare System (N.C.M.), Boston, and the Department of Medical Oncology, Davenport-Mugar Cancer Center, Cape Cod Hospital, Hyannis (T.H.O.) - all in Massachusetts; Myeloma Service, the Department of Medicine, Memorial Sloan Kettering Cancer Center (H. Hassoun, S.A.G.), and the Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai (S.J.), New York, the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (P.L.M., P.T.), and State University of New York Upstate Medical University, Syracuse (T.G.) - all in New York; the Winship Cancer Institute of Emory University, Atlanta (S.L., J.L.K.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M., E.S.); the Division of Medical Oncology and Fred Hutchinson Cancer Research Center, University of Washington, Seattle (E.N.L.); the Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte (P.M.V.), Duke University Medical Center, Durham (C.G.), and the Hematology and Oncology-Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem (D.D.H.) - all in North Carolina; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center (R.Z.O.), and Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital (R.T.K.), Houston, and Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas (L.D.A.) - all in Texas; the Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit (J.A.Z.), and the Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor (E.L.C.) - both in Michigan; the Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson (C.P.M.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (M.E.A.), and the Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.C.) - both in Pennsylvania; the Division of Hematology, Ohio State University Comprehensive Cancer Center, Columbus (A.M.K.); the Department of Bone Marrow Transplant and Cellular Therapy, University of Arizona, Tucson (K.G.); Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte (N.N.), and the Department of Medicine, Division of Hematology, Stanford University, Stanford (M.L.) - both in California; the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (M. Alsina); Vanderbilt University Medical Center, Nashville (R.F.C.); the Division of Hematology Oncology, Medical University of South Carolina, Charleston (H. Hashmi); Northern Light Eastern Maine Medical Center Cancer Care, Brewer (A.C.A.), and the Cancer Care Center of Maine, Bangor (T.H.O.); O'Neal Comprehensive Cancer Center, the University of Alabama at Birmingham, Birmingham (K.N.G.); the Center for International Blood and Marrow Transplant Research (CIBMTR), Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee (M.C.P.); the National Marrow Donor Program, CIBMTR, Minneapolis (A.F.); and the Department of Hematology (A.P., M. Attal) and Unit for Genomics in Myeloma (H.A.-L.), Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.) - both in France.
Article Synopsis
- A phase 3 trial analyzed the impact of adding autologous stem-cell transplantation (ASCT) to a treatment regimen involving lenalidomide, bortezomib, and dexamethasone (known as RVD) in patients with newly diagnosed multiple myeloma.
- Results showed that the group receiving RVD plus ASCT had a median progression-free survival of 67.5 months, compared to 46.2 months for those receiving just RVD, indicating a significantly lower risk of disease progression or death with ASCT.
- Although progression-free survival improved with ASCT, there was no overall survival advantage, with 5-year survival rates being comparable between the two
Genomic testing in 1019 individuals from 349 Pakistani families results in high diagnostic yield and clinical utility.
NPJ Genom Med
October 2020
CENTOGENE AG, Rostock, Germany.
We implemented a collaborative diagnostic program in Lahore (Pakistan) aiming to establish the genetic diagnosis, and to asses diagnostic yield and clinical impact in patients with suspected genetic diseases. Local physicians ascertained pediatric patients who had no previous access to genetic testing. More than 1586 genetic tests were performed in 1019 individuals (349 index cases, 670 relatives).
View Article and Find Full Text PDFPersonalized third-trimester fetal growth evaluation: comparisons of individualized growth assessment, percentile line and conditional probability methods.
J Matern Fetal Neonatal Med
September 2016
c Perinatology Research Branch, NICHD/NIH/DHHS , Detroit , MI , USA .
Objective: To compare third-trimester size trajectory prediction errors (average transformed percent deviations) for three individualized fetal growth assessment methods.
Methods: This study utilized longitudinal measurements of nine directly measured size parameters in 118 fetuses with normal neonatal growth outcomes. Expected value (EV) function coefficients and variance components were obtained using two-level random coefficient modeling.
To evaluate the effect of anticancer chemotherapeutic antigens on rat prostate, ten kinds of anticancer agents corresponding to the dose generally used for humans were intraperitoneally injected to 63-day-old Wistar rats. The anticancer agents were administered as follows: Cyclophosphamide (CPM) was used at the dose of 8 mg/kg for 7 days. Methotrexate (MTX), actinomycin-D (ACD) and cis-platinum (CDDP), 163 micrograms/kg, 8 micrograms/kg and 833 micrograms/kg for 5 days, respectively.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!